Not that it needed spelling out, but Organon’s CEO Kevin Ali wished to make sure there were no uncertainties. “That’s going to be the largest loss of exclusivity event in the history of the pharma market in the US,” he told attendees at the annual J.P. Morgan Healthcare Conference in January 2022.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?